Tillotts Pharma AG Sustainability Profile
Tillotts Pharma AG, headquartered in Switzerland (CH), is a prominent player in the pharmaceutical industry, specialising in gastrointestinal therapies. Founded in 2000, the company has established itself as a leader in developing innovative treatments for conditions such as inflammatory bowel disease and irritable bowel syndrome. With a strong presence in Europe and expanding operations in other regions, Tillotts Pharma is renowned for its unique product offerings, including the well-regarded 5-ASA compound, which sets it apart in the market. The company’s commitment to research and development has led to significant milestones, enhancing its reputation for quality and efficacy. Recognised for its contributions to patient care, Tillotts Pharma AG continues to solidify its market position through strategic partnerships and a focus on unmet medical needs, making it a trusted name in gastrointestinal health.
DitchCarbon Score
How does Tillotts Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tillotts Pharma AG's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tillotts Pharma AG's reported carbon emissions
Tillotts Pharma AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Zeria Pharmaceutical Co., Ltd., which may influence its climate-related initiatives and reporting practices. As of now, Tillotts Pharma AG has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, it is increasingly important for companies like Tillotts Pharma AG to adopt robust climate commitments and transparent emissions reporting to align with global sustainability goals. The cascading of data and initiatives from Zeria Pharmaceutical Co., Ltd. may provide a framework for future climate action, but specific details on emissions and reduction strategies remain unavailable at this time.
How Carbon Intensive is Tillotts Pharma AG's Industry?
How Carbon Intensive is Tillotts Pharma AG's Location?
Tillotts Pharma AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tillotts Pharma AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
